Cargando…
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
In colorectal cancer, immune effectors may be determinative for disease outcome. Following curatively intended combined-modality therapy in locally advanced rectal cancer metastatic disease still remains a dominant cause of failure. Here, we investigated whether circulating immune factors might corr...
Autores principales: | Meltzer, Sebastian, Kalanxhi, Erta, Hektoen, Helga Helseth, Dueland, Svein, Flatmark, Kjersti, Redalen, Kathrine Røe, Ree, Anne Hansen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085198/ https://www.ncbi.nlm.nih.gov/pubmed/27145458 http://dx.doi.org/10.18632/oncotarget.8995 |
Ejemplares similares
-
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
por: Kalanxhi, Erta, et al.
Publicado: (2016) -
Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
por: Hektoen, Helga Helseth, et al.
Publicado: (2015) -
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
por: Kalanxhi, Erta, et al.
Publicado: (2018) -
Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic Drugs: Study Design, Multiplex Methods, Molecular Networks
por: Ree, Anne Hansen, et al.
Publicado: (2014) -
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
por: Meltzer, Sebastian, et al.
Publicado: (2019)